The vaccine will be ready in the first quarter of 2021 and could be applied in Mexico a year earlier than in the rest of the countries.
This morning, the Government of Mexico announced a production agreement between AstraZeneca, the University of Oxford and the Slim Foundation to produce the British ChAdOx1 nCoV-19 vaccine (also known as AZD1222) against COVID-19 in Argentina and Mexico.
The president of Argentina, Alberto Fernández, was the first to advance the news on Wednesday night after ensuring that while his country will be in charge of manufacturing the asset, Mexico will be in charge of packaging and completing the initial production process of 150 million doses of vaccines, with the possibility of increasing to 250 million.
When will the vaccine be ready?
It is estimated that for the November the results of phase three are published of clinical trials, which is currently being carried out with 50 thousand volunteers in England, the United States, South Africa and Brazil.
If these clinical trials are successful, it will be a matter of time before the regulatory authority in Mexico, the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) begins a evaluation process for the vaccine to obtain a health record.
Once approved, a technology transfer process would begin in both Argentina and Mexico to begin produce AZD1222 vaccine during the first quarter of 2021.
Also read: The 6 vaccines against COVID-19 that are in a very advanced stage according to the WHO
Those in charge of producing the vaccine will be, on the one hand, the Argentine laboratory mAbxcience that will provide the active substance, while In Mexico, it will be the Liomont company that will complete the stabilization, manufacturing and packaging process to be distributed in Latin America and the Caribbean.
According to Marcelo Ebrard, Secretary of Foreign Relations, the agreement will allow Mexico will be one of the first countries where the vaccine is distributed throughout the world: “Instead of the vaccine being distributed in Mexico in more than a year, it will be advanced 6 or 7 months.”
How does the Oxford vaccine against COVID-19 that will be produced in Mexico work?
Sarah Gilbert, the scientist behind the development of the ChAdOx1 nCoV-19 vaccine. Photo: John Cairns / University of Oxford
The ChAdOx1 nCoV-19 vaccine (also known as AZD1222) is the most advanced with published results so far.
Developed by the Jenner Institute of the University of Oxford and the pharmaceutical AstraZeneca, it is an immunization based on ChAdOx1 technology, with a attenuated adenovirus vector and genetically modified, which in the clinical trials of the first two phases has shown that it is capable of generating a strong immune response.
In addition to producing antibodies, the vaccine causes the T cell immune response, lymphocytes that develop long-term cellular memory to fight pathogens.
On paper, this feature would cause a “Double protection” that would make ChAdOx1 nCoV-19 the most developed vaccine with published studies to date, above mRNA-1273 and Ad5-nCoV, the vaccines produced by Moderna Inc./United States and Cansino Biologics / China, respectively.
Learn more by reading: Oxford’s coronavirus vaccine produces ‘double protection’ that could last for years
Oxford vaccine research is led by Sarah Gilbert, a 58-year-old professor of vaccinology and immunologist with more than two decades of experience in vaccine development.
Sarah Gilbert, the scientist who tested the COVID-19 vaccine on her children
Coronavirus vaccines won’t arrive until early 2021: WHO